权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Vaccine and Treatment Evaluation Units

疫苗和治疗评估单位

基本信息

批准号：
10265658
负责人：
EVAN J ANDERSON
金额：
$ 204.46万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-09 至 2022-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10265658
关键词：
Acquired Immunodeficiency Syndrome Address Adult Anthrax disease Antibiotic Resistance Antimicrobial Resistance Area Biological Response Modifier Therapy Categories Centers for Disease Control and Prevention (U.S.)Childhood Clinical Clinical Protocols Clinical Research Clinical Sciences Clinical Trials Clinical Trials Unit Communicable Diseases Communities Complex Consent Databases Dedications Devices Diagnostic Disease Outcome Drug Kinetics Ebola Elderly Emerging Communicable Diseases End Point Assay Enrollment Ensure Environment Epidemic Ethnic Origin Evaluation Faculty Female Funding Generations Grant HIV Healthcare Systems Human Immunologic Tests Immunologics Immunology Individual Infection Influenza Influenza A Virus, H5N1 Subtype Influenza A Virus, H7N9 Subtype Influenza A virus Infrastructure Institutes Institution International Laboratories Laboratory Research Lead Leadership Malaria Mentors Mission Modeling National Institute of Allergy and Infectious Disease Outpatients Paper Participant Patients Pharmacy facility Phase Population Heterogeneity Positioning Attribute Prevention Procedures Prognostic Marker Protocols documentation Publications Publishing Quality Control Race Research Research Infrastructure Research Personnel Research Training Resources Risk Route Science Scientist Sexually Transmitted Diseases Site Smallpox Specimen Handling Structure Systems Biology Talents Therapeutic Training Training and Education Translational Research Tuberculosis Tularemia Universities Vaccines ZIKA base biodefense career development chikungunya clinical data warehouse clinical research site data management data quality design enteric pathogen flexibility global health improved outcome member neglected tropical diseases next generation novel pandemic disease pandemic influenza pathogen predictive marker pregnant prevent programs protocol development quality assurance racial and ethnic racial diversity recruit respiratory pathogen response retention rate square foot study population trial design vaccine delivery vaccine evaluation vaccine trial vaccinology

项目摘要

Project Summary/Abstract The currently NIAID-funded Vaccine and Treatment Evaluation Unit (VTEU) based at Emory University is ideally positioned to implement the mission of the Infectious Diseases Clinical Research Consortium (IDCRC) . The Emory VTEU is supported by Emory's rich scientific milieu with numerous synergistic grants and various thematic research centers covering all IDCRC scientific priority areas. The Emory VTEU infrastructure relies on two clinical research sites with a total of 16,000 square feet of clinical, laboratory, and pharmacy space and 83 faculty members and staff. Over the past decade as a funded VTEU, we have conducted 51 VTEU protocols, served as lead on 25 trials, performed endpoint assays for 17 studies, and published 22 high impact papers. We have enrolled ~3,000 participants, 55% are female and 37% from diverse racial and ethnic backgrounds with a retention rate of ~93%. With its flexible infrastructure, the Emory VTEU demonstrated surge capacity to contribute to pandemic influenza, Zika, Ebola, and biodefense efforts by prioritizing resources in funds and staffing. The Emory VTEU will build on the current surge capacity by strengthening our partnership with the Georgia Clinical and Translational Science Alliance and collaborating with well-established Emory international partners on a protocol-specific basis. Additionally, to date, our VTEU has trained 28 fellows and junior faculty. We will build on our significant record of accomplishment and advance the IDCRC mission by implementing the following specific aims: 1. Engage a broad range of Emory scientists with expertise in established and newly emerging infectious diseases in the core science of the IDCRC including concept generation and protocol development. 2. Leverage our access to a unique and diverse population and state-of-the-art research infrastructure to implement all components of the IDCRC science, including study conduct, data quality control and assurance procedures, data management, and good clinical, laboratory, and pharmacy practices. 3. Optimize our operational flexibility to further enhance our ability to provide surge capacity to address emerging infectious diseases and pandemic response. 4. Expand our mentoring capacity and enhance career development opportunities for early stage investigators in the areas of vaccinology, infectious diseases diagnostics, therapeutics, and prevention.

项目总结/文摘